Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of aflibercept dosing regimens in neovascular age-related macular degeneration
2013-000120-33Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Bayer. Primary endpoint: Change in ETDRS BCVA letter score for the study eye from baseline. Started Jun 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2013-000120-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000120-33.